Click to view the original PDF
The research report was released on August 10 to maintain the Betta Pharmaceuticals Co.Ltd(300558) overweight rating. Tianfeng Securities Co.Ltd(601162) predicts that the net profit attributable to the parent company in Betta Pharmaceuticals Co.Ltd(300558) 2021 will be 457 million yuan, a year-on-year decrease of 24.61%.
Main financial indicators and valuation
2021E
2022E
2023E
Total operating revenue (100 million yuan) 254335 million yuan eight thousand nine hundred and forty-seven point one seven
Net profit attributable to parent company (RMB 100 million) 457.6 million thirty-eight point four two
Earnings per share (yuan) 1.11 five hundred and twenty-two point zero three
Net assets per share (yuan) 10.6611 seven thousand seven hundred and thirteen point two nine
Price earnings ratio (PE) 83.5260 five thousand six hundred and forty-five point three three
Price to book ratio (PB) 8.637 eight hundred and twenty-six point nine two
Return on net assets (%) 10.3312 nine thousand one hundred and fifteen point two seven
Note: the data is obtained from the text of the research report.
Betta Pharmaceuticals Co.Ltd(300558) has received attention from 5 research reports of securities companies in recent month. The detailed data of the research report are shown in the table below:
Research report date
Organization abbreviation
Target price
This rating
details
August 10, 2021 Dongguan Securities – Recommended comments on 2021 interim report: Q2 performance achieved rapid growth and R & D continued to advance
2021-08-10 Zhongtai Securities Co.Ltd(600918) – buying performance was in line with expectations, and the two wheel drive main business of EGFR and alk inhibitors grew strongly
2021-08-10 China Securities Co.Ltd(601066) – buying performance meets expectations, and new products and indications are expected to enter medical insurance
The performance growth of 2021-08-10 Tianfeng Securities Co.Ltd(601162) – overweight was in line with expectations, and a variety of drugs in the field of lung cancer made progress
On August 10, 2021, Guosheng Securities – bought, performed well in the first half of the year, gained a lot, and achieved rapid growth in Q2
Disclaimer: This article is based on big data production and is for reference only. It does not constitute any investment suggestions. Therefore, the operator shall bear the operational risk.
